Growth hormone is a protein produced by the pituitary gland, a pea-sized structure at the base of the brain, and it orchestrates an enormous range of bodily functions far beyond what its name suggests. While it earned its name for driving childhood height, growth hormone also regulates how your body burns fat, builds muscle, maintains bone density, and even supports brain function throughout life. Its release is tightly controlled by a push-and-pull system of signals from the brain and the gut, and disruptions to that system can have consequences ranging from stunted growth in children to metabolic problems in adults.
How the Pituitary Gets Its Marching Orders
Growth hormone (GH) does not flow from the pituitary at a constant rate. It comes in pulses, and the pattern of those pulses is set by two opposing signals from the hypothalamus, a region of the brain sitting just above the pituitary. One signal, growth hormone-releasing hormone (GHRH), tells the pituitary to secrete GH. The other, somatostatin, tells it to stop. The interplay between these two signals creates an ultradian rhythm, a repeating cycle of GH bursts and quiet periods throughout the day.1PubMed. Physiology of growth hormone secretion and action2PubMed. Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion
That two-signal model held up for decades, but researchers have since found additional players. Ghrelin, a hormone released mainly by the stomach lining, also stimulates GH secretion. It works both directly on the pituitary and indirectly by boosting GHRH release and dampening somatostatin. Because ghrelin is also tied to appetite and energy balance, it provides a link between nutritional status and growth signaling. More recently, hormones involved in mineral balance, such as klotho, have been found to influence GH release as well, further expanding the picture of how the body fine-tunes this system.3PubMed Central. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It
What Growth Hormone Actually Does
Once GH enters the bloodstream, it works in two ways. It binds directly to growth hormone receptors on cells throughout the body, triggering internal signaling cascades that promote cell growth and metabolic changes. It also acts indirectly by stimulating the liver and other tissues to produce insulin-like growth factor 1 (IGF-1), which carries out many of GH’s downstream effects. This two-pronged system, sometimes called the GH-IGF-1 axis, is at the heart of nearly everything GH does.4PubMed. Growth hormone signaling and clinical implications: from molecular to therapeutic perspectives
In children and adolescents, the most visible effect is longitudinal bone growth. Long bones grow at cartilage zones called growth plates. GH acts on the early-stage cartilage cells in these plates, prompting them to start dividing, while IGF-1 then drives those primed cells to multiply more rapidly. The combined effect is the elongation of bones that adds height during childhood and adolescence.5PubMed. Hormonal regulation of longitudinal bone growth The process depends on many other hormones as well, including thyroid hormone and estrogen, and it eventually stops once the growth plates fuse, typically by the late teens.6PubMed Central. The growth plate: a physiologic overview
Beyond growth, GH plays a central role in metabolism at every stage of life. Its most prominent metabolic action is increasing the breakdown of stored fat, releasing fatty acids into the bloodstream for use as fuel. It also promotes protein synthesis and reduces protein breakdown, particularly in muscle. On the flip side, GH acts as a counterweight to insulin: it opposes insulin’s effects on glucose uptake in the liver and other tissues, which can raise blood sugar levels. This insulin-opposing action is why excess GH, whether from a tumor or from outside supplementation, can push people toward glucose intolerance.7Endocrine Reviews. Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Sleep, Exercise, and Fasting as GH Triggers
You have probably heard that sleep is important for GH levels, and the evidence backs that up. In healthy people, the single largest GH pulse of the day occurs shortly after falling asleep, during the first bout of deep (slow-wave) sleep. When researchers studied what happens during total sleep deprivation, they found that this sleep-related pulse is suppressed, though the body partially compensates by releasing more GH during the daytime hours that follow.8PubMed. Effect of sleep deprivation on overall 24 h growth-hormone secretion
Partial sleep loss, which better describes the reality for many people, produces a different pattern. In one study, when healthy men accumulated a sleep debt by sleeping fewer hours than normal over several nights, their GH secretion shifted from a single post-sleep pulse to a two-pulse pattern: one before sleep onset and one after. The body appeared to be recalibrating its GH timing to squeeze in release wherever it could.9PubMed. Adaptation of the 24-h growth hormone profile to a state of sleep debt
Exercise is another potent stimulus. During a bout of intense exercise, GH concentrations can climb rapidly above 10 ng/ml. This spike activates downstream signaling in muscle tissue and, after a delay of several hours, increases IGF-1 production locally in the muscle. Fasting also raises GH, though the pattern is spikier and less consistent than the exercise response. In one study, fasting produced roughly a three-fold increase in cumulative GH exposure over several hours, with more sporadic bursts rather than the clean peak seen with exercise.10PubMed. Exercise and fasting activate growth hormone-dependent myocellular signal transducer and activator of transcription-5b phosphorylation and insulin-like growth factor-I messenger ribonucleic acid expression in humans
When the Body Makes Too Little
Growth hormone deficiency (GHD) in children leads to slower growth than expected and, if untreated, significantly shorter adult height. Diagnosing it is not straightforward, since GH levels naturally fluctuate so much that a single blood test is unreliable. Instead, clinicians use stimulation tests: they administer a substance that should trigger a GH spike and then measure whether the response is adequate. The insulin tolerance test (ITT), where a dose of insulin is given to drop blood sugar and provoke a GH response, remains the best-validated option. A peak GH response below about 3 µg/l is generally used to define severe GHD in adults.11European Journal of Endocrinology. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement Other tests exist because the ITT has limitations: it is contraindicated in people with seizure disorders or heart disease, and in very obese individuals the results can overlap with those seen in true GHD.12PubMed. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients
Once confirmed, GHD is treated with daily injections of recombinant human GH. Early GH therapy, before the development of recombinant technology, relied on GH extracted from cadaver pituitary glands, which limited supply and carried a rare but serious risk of prion disease. The switch to lab-made recombinant GH in the mid-1980s eliminated that risk and made therapy widely available.13PubMed Central. History of growth hormone therapy Treatment is individualized: the dose is adjusted based on the patient’s response rather than set at a fixed level.14PubMed Central. Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology
Adults with GHD experience a different set of problems. Rather than height loss (the growth plates have already closed), they tend to accumulate abdominal fat, lose lean muscle mass, and have reduced bone density.15PubMed. Growth hormone (GH) status and body composition in normal ageing and in elderly adults with GH deficiency In a landmark trial, GH-deficient adults who received six months of recombinant GH gained an average of about 5.5 kg of lean body mass and lost a similar amount of fat mass, with no change in overall body weight. Their basal metabolic rate also increased, and cholesterol levels improved.16PubMed. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
When the Body Makes Too Much
The mirror image of deficiency is excess. When a pituitary tumor churns out GH beyond what the body needs, the result in adults is acromegaly, a condition characterized by gradual enlargement of the hands, feet, and facial features, along with a string of systemic problems. The excess GH drives IGF-1 overproduction, which in turn can cause joint disease, cardiovascular complications, impaired glucose metabolism, and increased mortality risk.17PubMed. Acromegaly: clinical features at diagnosis
If the same kind of tumor develops in a child or adolescent before the growth plates close, the outcome is pituitary gigantism, which accounts for up to about 5% of GH-excess cases. Both conditions can lead to cardiac changes: studies comparing young adults with gigantism and acromegaly have found increased heart muscle mass and abnormal filling patterns in both groups. Interestingly, glucose metabolism problems were more common in acromegaly patients, even though those with gigantism had been exposed to high GH levels for a longer stretch of their lives.18PubMed. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism
The Somatopause and Aging
GH secretion does not remain constant throughout adulthood. Starting around age 30, production drifts downward steadily, a phenomenon sometimes called the somatopause. By older age, GH output and IGF-1 levels are a fraction of what they were in youth. This decline parallels familiar changes in body composition: more belly fat, less muscle mass, weaker bones, reduced energy.19PubMed Central. Growth hormone and aging: a challenging controversy
That correlation has fueled enormous interest in using GH as an anti-aging therapy. Clinical trials using repeated doses of GHRH in healthy older men have restored GH and IGF-1 levels toward youthful ranges and improved body composition.20Frontiers in Aging. Growth hormone and aging: a clinical review But the enthusiasm comes with a serious caveat. Long-term GH replacement in the elderly carries risks of metabolic disturbances, cardiovascular complications, and potentially accelerated cancer growth. This is why GHRH-based approaches, which coax the body’s own pituitary to release more GH rather than flooding it with exogenous hormone, have drawn attention as a potentially safer alternative, though they are still under investigation.21PubMed. The Role of Growth Hormone-Releasing Hormone and the Hypothalamic-Pituitary-Somatotropic Axis in Aging: Potential Therapeutic Applications and Risks
In a paradox that researchers are still working through, the age-related decline in GH may not be purely harmful. Lower GH and IGF-1 signaling appear to offer some protection against cancer and other age-related diseases. Animal studies consistently show that reduced GH signaling extends lifespan, which raises the uncomfortable possibility that reversing the somatopause might buy short-term vitality at the cost of long-term health.19PubMed Central. Growth hormone and aging: a challenging controversy
GH, IGF-1, and Cancer Risk
The relationship between growth signaling and cancer is not just a theoretical concern for aging research. Epidemiological studies have consistently found that higher circulating IGF-1 levels are associated with increased risk of several common cancers, including breast, prostate, and colorectal cancer.22PubMed. Insulin-like growth factors and cancer A large prospective study in Europe reported that higher IGF-1 was linked to about a 25% increase in breast cancer risk and roughly a 31% increase in prostate cancer risk after adjusting for other factors.23The Journal of Clinical Endocrinology & Metabolism. IGF-1 and Risk of Morbidity and Mortality From Cancer, Cardiovascular Diseases, and All Causes in EPIC-Heidelberg There is also interest in whether elevated IGF-1 promotes the development of second cancers after an initial diagnosis.24PubMed Central. Is there a role for IGF‐1 in the development of second primary cancers?
These associations do not mean GH therapy causes cancer in every patient who receives it. The relationship is probabilistic and modulated by many other factors. But it is a key reason why GH therapy requires clear medical justification rather than being handed out as a wellness supplement, and why monitoring IGF-1 levels during treatment matters.
GH in Athletic Doping
Growth hormone has been banned by the World Anti-Doping Agency for decades, yet it remains widely used in professional and amateur sports. Athletes believe it builds muscle, accelerates recovery, and improves performance. The scientific evidence for those beliefs, however, is surprisingly thin. In healthy adults and trained athletes, GH does increase lean body mass, though part of that effect may be fluid retention rather than true muscle growth. Controlled studies have found no improvement in muscle strength, power, or aerobic capacity. The one area where a benefit has been measured is anaerobic exercise capacity, meaning short, explosive efforts.25PubMed. Growth hormone and physical performance
The gap between perception and evidence is striking. Reviews of the doping literature consistently describe the ergogenic evidence as weak, a fact that is “not widely appreciated in athletic circles or by the general public.”26Endocrine Reviews. Growth Hormone Doping in Sports: A Critical Review of Use and Detection Strategies Meanwhile, the health risks of high-dose, prolonged GH use, including insulin resistance, joint pain, soft tissue swelling, and the cardiovascular and metabolic problems seen in acromegaly, are real and well documented.
Detection remains a cat-and-mouse game. Because injected recombinant GH is chemically identical to one of the body’s own GH forms, catching doping is tricky. The isoform test, which exploits the fact that recombinant GH is a single molecular form while natural GH is a mix of several forms, works but has a detection window of only about 12 to 24 hours after the last dose. A newer biomarker test measures the downstream effects of GH, particularly increases in IGF-1 and a collagen marker, and extends the window to one to two weeks, but it faces its own technical challenges.27PubMed Central. Human growth hormone doping in sport
Growth Hormone Secretagogues
Rather than giving GH itself, another therapeutic strategy is to use compounds that stimulate the body to release its own GH. These are collectively called growth hormone secretagogues (GHSs), and they include agonists of the ghrelin receptor as well as compounds that mimic GHRH. The logic is appealing: by working through the body’s existing regulatory machinery, secretagogues may preserve the natural pulsatile pattern of GH release and potentially produce fewer side effects than direct GH injection.28JCSM Rapid Communications. Growth hormone secretagogues: history, mechanism of action, and clinical development
In older adults, secretagogues have shown promise. In clinical studies, they have been able to reproduce a young-adult GH secretion profile in elderly subjects, accompanied by increases in bone mineral density and lean mass, along with modest improvements in strength.29Endocrine Reviews. Development of Growth Hormone Secretagogues This category includes compounds like MK-677, a non-peptide ghrelin receptor agonist that has been studied extensively. Research into how these compounds interact with the ghrelin receptor has revealed unexpected complexity: some act as straightforward agonists, while others can amplify or dampen the effect of the body’s own ghrelin, depending on the compound.30Molecular Endocrinology. Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling
GH and the Brain
One of the less widely known roles of GH is its influence on the brain. GH receptors are found in brain regions involved in learning and memory, and GH is believed to affect the signaling circuits that underlie the brain’s ability to form new connections. In animal studies and in human patients, GH replacement has been shown to counteract a range of cognitive and behavioral impairments linked to GH deficiency.31PubMed. Growth hormone and cognitive function
In children with isolated GHD, brain imaging has revealed measurable structural differences. Compared with healthy controls, children with GHD had lower scores on IQ tests and motor performance assessments. Their brain scans showed smaller volumes in several key structures, including the hippocampus and thalamus, and abnormalities in white matter tracts that connect distant brain regions. These structural differences correlated with the cognitive deficits: children with more pronounced white matter changes tended to have lower IQ and processing speed scores.32Brain. Effect of growth hormone deficiency on brain structure, motor function and cognition Whether GH treatment reverses these structural and cognitive effects is an open research question, but the findings underscore that GH does more for the developing body than just add inches.
Growth Hormones in Agriculture
Human medicine is not the only arena where growth hormones matter. In dairy farming, recombinant bovine somatotropin (rbST) has been used since 1994 in the United States to boost milk production in cows. The hormone is species-specific, meaning the bovine version does not bind to human GH receptors, and it works by repartitioning the cow’s metabolic resources toward milk production. A meta-analysis of rbST use found that treated cows produced about 4 kg more milk per day, with no change in the concentration of milk components like fat and protein, and no effect on somatic cell counts or rates of clinical mastitis.33PubMed. Meta-analysis of the effects of sometribove zinc suspension on the production and health of lactating dairy cows
Despite those findings, rbST has been banned in the European Union and several other countries, largely over animal welfare concerns and the precautionary principle rather than demonstrated harm to consumers. More detailed profiling of milk from rbST-treated cows has shown subtle compositional shifts, including a tendency toward a less saturated fatty acid profile and slight changes in mineral content.34PubMed Central. Impact of Recombinant Bovine Somatotropin on Bovine Milk Composition and Fatty Acidome: A Multidose Longitudinal Study In the U.S., commercial uptake has been extensive, and milk labeled as rbST-free occupies a niche market.35PubMed. Bovine somatotropin and lactation: from basic science to commercial application
How Growth Hormone Evolved
Growth hormone is not a human invention; it is ancient biology. The molecule exists in all vertebrates, from sharks to songbirds. What is interesting is that its evolutionary history is not a smooth, gradual story of small changes. Analysis of GH genes across vertebrates reveals long stretches of near-stasis, where the molecule barely changed over millions of years, punctuated by sudden bursts of rapid evolution. These bursts occurred independently in several lineages, including amphibians, sharks, and bony fish. Researchers have argued that these episodes of rapid change reflect selection pressure tied to new functions the hormone took on in different groups, expanding beyond its ancestral growth-promoting role.36PubMed. The molecular evolution of vertebrate growth hormones: a pattern of near-stasis interrupted by sustained bursts of rapid change That evolutionary flexibility helps explain why GH today is involved in so many seemingly unrelated processes: it has been recruited and repurposed many times across the vertebrate family tree.